Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models.
Enzyme replacement therapy (ERT) can potentially result in an immunological response to the introduced protein. The immunological response by Mucopolysaccharidosis type VI (MPS VI) cats to recombinant human N-acetylgalactosamine 4-sulfatase (rh4S) ERT has been investigated. Plasma antibody titres to rh4S were detected in untreated MPS VI and normal control cats, but the antibody titres to rh4S were higher in ERT treated MPS VI cats. The reactivity by cats to rh4S did not appear to be just due to species cross reactivity, as plasma antibodies from normal control, MPS VI and MPS VI ERT cats reacted equally with feline and human 4-sulfatase. Normal control and MPS VI human plasma also had antibody titres to rh4S. Plasma antibodies to rh4S, from an ERT treated cat, could be temporarily removed from circulation by enzyme infusion, confirming specificity for rh4S and indicating a possible window for ERT in the absence of antibody. In enzyme distribution studies with 3H-rh4S, evidence of altered targeting, and enzyme inactivation and degradation were observed in high compared to low titre rats. In high titre rats, the observed loss of 3H-label from vacuolar organelles of the liver may represent either degradation of antibody bound 3H-rh4S for reutilisation within the liver, or antigen presentation. The development of high titre antibody may have a detrimental effect on the efficacy of ERT.
Brooks
D A
DA
Department of Chemical Pathology, Women's and Children's Hospital, North Adelaide South Australia. dbrooks@medicine.adelaide.edu.au
King
B M
BM
Crawley
A C
AC
Byers
S
S
Hopwood
J J
JJ
D000818:Animals; D000906:Antibodies / Q000097:blood / Q000276:immunology; D000917:Antibody Formation; D001007:Anxiety / Q000209:etiology; D002415:Cats; D003490:Cyanosis / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D005334:Fever / Q000209:etiology; D006801:Humans; D009087:Mucopolysaccharidosis VI / Q000188:drug therapy* / Q000276:immunology; D020051:N-Acetylgalactosamine-4-Sulfatase; D051381:Rats; D011994:Recombinant Proteins / Q000009:adverse effects; D012119:Respiration / Q000187:drug effects; D013429:Sulfatases / Q000009:adverse effects* / Q000276:immunology / Q000493:pharmacokinetics; D014018:Tissue Distribution; D014839:Vomiting / Q000209:etiology
D000906:Antibodies; D011994:Recombinant Proteins; D013429:Sulfatases; D020051:N-Acetylgalactosamine-4-Sulfatase